Skip to main content

Table 2 Association between PTGS2 genotypes and breast cancer risk in the Nurses' Health Study

From: A polymorphism in the 3' untranslated region of the gene encoding prostaglandin endoperoxide synthase 2 is not associated with an increase in breast cancer risk: a nested case-control study

SNP

Genotype

Cases (percentage)

Controls (percentage)

OR (95% CI)a

PTGS2_20417

G/G

865 (69.6)

1,185 (69.1)

1.00 (reference)

 

G/C

336 (27.0)

485 (28.3)

0.93 (0.78–1.10)

 

C/C

42 (3.4)

45 (2.6)

1.28 (0.82–2.02)

    

p trend = 0.94

PTGS2_5277

G/G

875 (71.0)

1,217 (71.0)

1.00 (reference)

 

G/C

322 (26.1)

464 (27.1)

1.00 (0.84–1.19)

 

C/C

35 (2.8)

34 (2.0)

1.35 (0.81–2.26)

    

p trend = 0.55

PTGS2_5209

T/T

834 (69.4)

1,171 (69.5)

1.00 (reference)

 

T/G

330 (27.5)

472 (28.0)

0.97 (0.82–1.16)

 

G/G

38 (3.2)

43 (2.6)

1.24 (0.77–2.00)

    

p trend = 0.81

PTGS2_5275

T/T

541 (43.3)

699 (40.6)

1.00 (reference)

 

T/C

567 (45.4)

808 (47.0)

0.88 (0.75–1.04)

 

C/C

141 (11.3)

213 (12.4)

0.80 (0.62–1.03)

    

p trend = 0.05

PTGS2_4648298

A/A

1,180 (95.4)

1,654 (96.3)

1.00 (reference)

 

A/G + G/G

57 (4.6)

63 (3.7)

1.29 (0.88–1.88)

  1. aUnconditional logistic regression controlled for age, BMI at age 18 years, menopausal status at diagnosis, history of benign breast disease, and family history of breast cancer. CI, confidence interval; PTGS2, prostaglandin endoperoxide synthase 2; OR, odds ratio; SNP, single-nucleotide polymorphism.